Rationalized Tailored Targeted Therapy for Cancer: The Triple-T Service
Triple-T combines the expertise of 2 companies specialized in kinase activity and genomic profiling with academically developed technologies to provide doctors and patients with information on druggable and drug-resistance pathways of individual lung tumors. This first commercial service of its kind will enable clinicians to rationally choose kinase inhibitor(s) to treat (therapy resistant) patients better. Services will be later extended to other cancers.
1 555 450.00€
Cellular and Molecular Biology